Kratos Research Labs

KRL10 RUO launch access: documentation-led small-order review, product docs, and gated catalog access after RUO acknowledgement. Send KRL10 review request. Research use only; not for human or veterinary use.

What Does the Published Research Say About CJC-1295 Without DAC?

Written by

mollybolt

in

Research Context

This synthesis isolates what the included literature shows—and does not show—about CJC-1295 without DAC. The packet contains: two human study sources (a pharmacodynamic study in healthy adults and a human biomarker study; plus a clinical trial registry entry in a disease-specific context), one netnographic review source, and three preclinical/analytical sources. Importantly, the direct human data provided (e.g., [pubmed:16352683], [pubmed:19386527]) describe a long-acting CJC-1295 GHRH analog; these should not be treated as interchangeable with a non-DAC variant.

Key Takeaway

Most direct human findings in this packet concern a long-acting CJC-1295 formulation, not a non-DAC variant. Evidence shows GH/IGF-1 biomarker changes and lists a disease-specific trial, but no human outcome data specific to a non-DAC variant are included.

Direct Answer

Published research in this packet shows that a long-acting CJC-1295 GHRH analog can prolong GH and IGF-1 secretion in healthy adults and alter serum protein profiles (biomarker-level findings) [pubmed:16352683][pubmed:19386527]. A clinical trial was registered to evaluate CJC-1295 in HIV-associated visceral obesity, but no peer-reviewed outcomes are provided here [clinicaltrials:NCT00267527]. Netnographic review literature documents non-medical use narratives [pubmed:26771670]. Analytical studies in equine matrices describe detection methods, not therapeutic effects [pubmed:30938069][pubmed:30489688]. These sources do not establish clinical outcomes for a non-DAC CJC-1295 variant.

—

Direct Human Evidence

  • Pharmacodynamic study (healthy adults): A long-acting CJC-1295 GHRH analog produced prolonged stimulation of GH and IGF-1 secretion. Context noted that native GHRH has short duration, motivating evaluation of longer-acting analogs [pubmed:16352683].
  • Human biomarker/mechanistic study (normal adults): Activation of the GH/IGF-1 axis by CJC-1295 (long-acting GHRH analog) was associated with changes in serum protein profiles. This is biomarker-level/mechanistic evidence and not controlled clinical outcome data [pubmed:19386527].
  • Disease-specific clinical trial registry entry: A study was registered to evaluate CJC-1295 in HIV patients with visceral obesity; the packet does not provide peer-reviewed outcomes from this trial [clinicaltrials:NCT00267527].

Variant alignment clarification: The human studies above pertain to a long-acting CJC-1295 formulation. Given this article’s focus on “CJC-1295 without DAC,” these data should not be used as stand-in evidence for a non-DAC variant.

—

Review and Observational Context

  • Netnography of female use narratives: Documents online “folk pharmacology” describing interests such as muscle enhancement, fat loss, and skin appearance related to CJC-1295. This frames context but does not constitute primary human outcome evidence [pubmed:26771670].

—

Preclinical, Mechanistic, and Analytical Evidence

  • Analytical method development (equine plasma):
  • LC–MS/MS method to confirm CJC-1295 in equine plasma [pubmed:30938069].
  • Immuno-PCR screening for GHRH analogs in equine plasma [pubmed:30489688].

These are analytical/anti-doping methods, not therapeutic or outcome studies.

  • Human biomarker/mechanistic example (for clarity, still human, not outcomes): Serum protein profile changes consistent with GH/IGF-1 axis activation following exposure to a long-acting GHRH analog [pubmed:19386527]. This informs mechanism/biomarkers but not clinical efficacy.

These findings should not be presented as established human therapeutic outcomes.

—

What Is Not Established

  • No direct human outcome data specific to a non-DAC CJC-1295 variant are included in this packet.
  • Dosing and general safety across off-label or non-study populations are not addressed here.
  • Biomarker changes (GH/IGF-1, serum protein profiles) do not establish clinical benefit [pubmed:16352683][pubmed:19386527].
  • Extrapolation from a disease-specific registry entry (HIV-associated visceral obesity) to broader populations or indications is not supported without published outcomes [clinicaltrials:NCT00267527].
  • Analytical method papers in equine models are not evidence of therapeutic effects [pubmed:30938069][pubmed:30489688].

—

Conclusion

Within this packet, human evidence centers on long-acting CJC-1295 analogs that modulate GH/IGF-1 and associated biomarkers, plus a trial registered in a specific disease context without outcomes provided. These sources do not establish clinical outcomes for a non-DAC CJC-1295 variant, and they do not support generalized wellness, aesthetic, or performance claims.

—

FAQ

  • Does this packet include human outcome data for a non-DAC CJC-1295 variant?
  • No. The human evidence provided pertains to a long-acting formulation; no direct human outcome data specific to a non-DAC variant are included.
  • What human findings are reported for CJC-1295 in this packet?
  • Prolonged GH and IGF-1 secretion in healthy adults and serum protein profile changes consistent with GH/IGF-1 axis activation—both biomarker-level findings, not demonstrated clinical outcomes [pubmed:16352683][pubmed:19386527].
  • Is there a disease-specific clinical trial?
  • A study in HIV-associated visceral obesity is registered, but this packet does not include peer-reviewed outcome data from that trial [clinicaltrials:NCT00267527].
  • Do the equine detection studies inform therapeutic effects in humans?
  • No. They describe analytical methods for detecting CJC-1295 or related analogs in equine plasma, not therapeutic outcomes [pubmed:30938069][pubmed:30489688].
  • Can biomarker changes be interpreted as proof of benefit?
  • No. Mechanistic/biomarker signals (e.g., GH/IGF-1 increases, serum protein shifts) do not establish clinical efficacy [pubmed:16352683][pubmed:19386527].

—

References

  • Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. https://pubmed.ncbi.nlm.nih.gov/16352683/ [pubmed:16352683]
  • Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. https://pubmed.ncbi.nlm.nih.gov/26771670/ [pubmed:26771670]
  • A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. https://pubmed.ncbi.nlm.nih.gov/30938069/ [pubmed:30938069]
  • An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. https://pubmed.ncbi.nlm.nih.gov/30489688/ [pubmed:30489688]
  • Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. https://pubmed.ncbi.nlm.nih.gov/19386527/ [pubmed:19386527]
  • A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. https://clinicaltrials.gov/study/NCT00267527 [clinicaltrials:NCT00267527]
  • PubChem compound record: CJC 1295. https://pubchem.ncbi.nlm.nih.gov/compound/91971820 [pubchem:91971820]
  • Google Patents search for CJC-1295. https://patents.google.com/?q=CJC-1295 [patent_search:cjc-1295]

More posts